Related Experiment Video
Updated: Jul 19, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Reactive thrombocytosis associated with enoxaparin
Margaret C Hummel1, Bryan C Morse, Lloyd E Hayes
1Department of Pharmacy, Clinical Services, Greenville Hospital System University Medical Center, Greenville, South Carolina 29605, USA.
A 42-year-old man was hospitalized for a closed head injury caused by a bicycle accident. On hospital day 8, he developed thrombocytosis. Eleven days later, his platelet count reached 1005 x 10(3)/mm(3). A review of his drug therapy indicated enoxaparin as a potential reversible cause of reactive thrombocytosis. Enoxaparin was discontinued, and the patient's platelet count declined, eventually normalizing 6 days later. At that time, enoxaparin was restarted; this resulted in an increase in his platelet count that peaked 8 days later at 920 x 10(3)/mm(3). After each occurrence of thrombocytosis, enoxaparin was switched to unfractionated heparin in combination with sequential compression devices for deep vein thrombosis prophylaxis. No complications secondary to thrombocytosis were noted. Our patient's experience suggests that unfractionated heparin may be substituted for enoxaparin if this adverse effect is suspected.
A 42-year-old man was hospitalized for a closed head injury caused by a bicycle accident. On hospital day 8, he developed thrombocytosis. Eleven days later, his platelet count reached 1005 x 10(3)/mm(3). A review of his drug therapy indicated enoxaparin as a potential reversible cause of reactive thrombocytosis. Enoxaparin was discontinued, and the patient's platelet count declined, eventually normalizing 6 days later. At that time, enoxaparin was restarted; this resulted in an increase in his platelet count that peaked 8 days later at 920 x 10(3)/mm(3). After each occurrence of thrombocytosis, enoxaparin was switched to unfractionated heparin in combination with sequential compression devices for deep vein thrombosis prophylaxis. No complications secondary to thrombocytosis were noted. Our patient's experience suggests that unfractionated heparin may be substituted for enoxaparin if this adverse effect is suspected.
More Related Videos
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...

